Sign Out
Hypertension: Treatment of hypertension.
Heart failure: Treatment of heart failure (NYHA class II-IV) in adult patients receiving standard therapy such as diuretics, digitalis and either angiotensin-converting enzyme (ACE) inhibitors or beta-blockers but not both; presence of all these standard therapies is not mandatory.
Valpres improves morbidity in these patients, primarily via reduction in hospitalization for heart failure. Valpres also slows the progression of heart failure, improves NYHA functional class, ejection fraction and signs and symptoms of heart failure and improves quality of life versus placebo (see PHARMACOLOGY under Actions).
Post-myocardial infarction: Valpres is indicated to improve survival following myocardial infarction in clinically stable adult patients with signs, symptoms or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction (see PHARMACOLOGY under Actions).
